GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down
U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.
GSK Acquires Nuvalent for $10.6 Billion
- GSK to buy US cancer treatment firm Nuvalent for $10.6bn The Guardian —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Argus —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Standard —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Independent —
- GSK agrees to buy US cancer drug firm Nuvalent in £8bn deal Yorkshire Post —